Prosenze (leuprorelin depot) / Camurus - LARVOL DELTA

[VIRTUAL] Quality of life of patients with hormone-dependent advanced prostate cancer receiving palliative treatment with Leuprorelin depot injection (Lutrate®) – interim results from a non-interventional study in Germany (EMUC 2020) - "Conclusions The GNRH agonist leuprorelin depot injection maintains QoL in aPCA pts measured by the PORPUS-P score. It is an effective and well tolerated treatment option for pts with a hormone sensitive aPCa."

Clinical • HEOR • Observational data • Genito-urinary Cancer • Oncology • Palliative care • Prostate Cancer • Solid Tumor

"New measures to avoid handling errors w/ leuprorelin depot medicines: errors reported included incorrect use of needle or syringe causing medicine to leak and failure to inject leuprorelin properly 👉Review by PRAC https://t.co/Wcy0WGUXsE #oncologynews" (@myESMO)

Oncology

"The PRAC concluded a review of hormone replacement therapy (#HRT) and recommended new measures for #Leuprorelin depot medicines: 👉https://t.co/LKabrGtS8G" (@EMA_News)

"Leuprorelin Depot Handling Errors Prompt EMA Review https://t.co/4NIeTJ2KXE via @medscape" (@StefanANASTASE3)